- Multi-Specific CAR T
- Heme Malignancies
- 50% of Lead Selection
*Phase 3 may not be required if the preceding phase is registrational.
CARGO is developing a multi-specific CAR T with CD2 co-stimulation designed to overcome multiple resistance mechanisms – antigen loss, co-stimulation (CD58) loss and lack of persistence. With a multi-targeted approach, it has the potential to treat several hematologic malignancy types. CARGO is in the process of selecting a development candidate for this program that it plans to advance into IND-enabling studies.